Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

ProscarProscar

( finasteride, MSD )

 

PROSCAR (finasteride, MSD), a synthetic 4-azasteroid compound is a specific inhibitor of Type II 5α-reductase , an intracellular enzyme which metabolizes testosterone into the more potent androgen dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. PROSCAR is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.

 

In the PROSCAR Long-Term Efficacy and Safety Study (PLESS), the effect of therapy with PROSCAR on BPH-related urologic events (surgical intervention [e.g., transurethal resection of the prostate and prostatectomy] or acute urinary retention requiring catheterization) was assessed over a 4-year period in 3016 patients with moderate to severe symptoms of BPH. In this double-blind, randomized, placebo-controlled multicenter study, treatment with PROSCAR reduced the risk of total urologic events by 51% and was also associated with a marked and sustained regression in prostate volume, and a sustained increase in maximum urinary flow rate and improvement in symptoms.

 

INDICATIONS

PROSCAR is indicated for the treatment and control of benign prostatic hyperplasia (BPH) and for the prevention of urologic events to:

-- Reduce the risk of acute urinary retention.

-- Reduce the risk of surgery including transurethral resection of the prostate (TURP) and prostatectomy.

 

PROSCAR causes regression of the enlarged prostate, improves urinary flow and improves the symptoms associated with BPH.

 

Patients with an enlarged prostate are the appropriate candidates for therapy with PROSCAR.

 

PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed 4 point increase in ALA symptom score).

 

DOSAGE AND ADMINISTRATION

The recommended dosage is one 5-mg tablet daily with or without food.

DOSAGE IN RENAL INSUFFICIENCY

No adjustment in dosage is required in patients with varying degrees of renal insufficiency (creatinine clearances as low as 9 mL/min) as pharmacokinetic studies did not indicate any change in the disposition of finasteride.

 

DOSAGE IN THE ELDERLY

No adjustment in dosage is required although pharmacokinetic studies indicated the elimination of finasteride is somewhat decreased in patients more than 70 years of age.

 

CONTRAINDICATIONS

PROSCAR is not indicated for use in women or children. PROSCAR is contraindicated in the following:

Hypersensitivity to any component of this product.

Pregnancy - Use in women when they are or may potentially be pregnant (see PRECAUTIONS. PREGNANCY and EXPOSURE TO FINASTERIDE - RISK TO MALE FETUS).

 

PRECAUTIONS

GENERAL

Patients with large residual urine volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.

 

EFFECTS ON PSA AND PROSTATE CANCER DETECTION

No clinical benefit has yet been demonstrated in patients with prostate cancer treated with PROSCAR. Patients with BPH and elevated prostate-specific antigen (PSA) were monitored in controlled clinical studies with serial PSAs and prostate biopsies. In these BPH studies, PROSCAR did not appear to alter the rate of prostate cancer detection and the overall incidence of prostate cancer was not significantly different in patients treated with PROSCAR or placebo.

 

Digital rectal examinations as well as other evaluations for prostate cancer are recommended prior to initiating therapy with PROSCAR and periodically thereafter. PSA is also used for prostate cancer detection. Generally, a baseline PSA >10 ng/mL (Hybritech) prompts further evaluation and consideration of biopsy; for PSA levels between 4 and 10 ng/mL, further evaluation is advisable. There is considerable overlap in PSA levels among men with and without prostate cancer Therefore, in men with BPH, PSA values within the normal reference range do not rule out prostate cancer, regardless of treatment with PROSCAR. A baseline PSA < 4 ng/mL does not exclude prostate cancer.

 

PROSCAR causes a decrease in serum PSA concentrations by approximately 50% in patients with BPH, even in the presence of prostate cancer. This decrease in serum PSA levels in patients with BPH treated with PROSCAR should be considered when evaluating PSA data and does not rule out concomitant prostate cancer. This decrease is predictable over the entire range of PSA values, although it may vary in individual patients. Analysis of PSA data from over 3000 patients in the 4-year, double-blind, placebo-controlled PROSCAR Long-Term Efficacy and Safety Study (PLESS) confirmed that in typical patients treated with PROSCAR for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men. This adjustment preserves the sensitivity and specificity of the PSA assay and maintains its ability to detect prostate cancer.

 

Any sustained increase in PSA levels of patients treated with finasteride should be carefully evaluated, including consideration of non-compliance to therapy with PROSCAR.

 

Percent free PSA (free to total PSA ratio) is not significantly decreased by PROSCAR. The ratio of free to total PSA remains constant even under the influence of PROSCAR. When percent free PSA is used as an aid in the detection of prostate cancer, no adjustment to its value is necessary.

 

DRUG/LABORATORY TEST INTERACTIONS

EFFECT ON LEVELS OF PSA

Serum PSA concentration is correlated with patient age and prostatic volume, and prostatic volume is correlated with patient age. When PSA laboratory determinations are evaluated, consideration should be given to the fact that PSA levels decrease in patients treated with PROSCAR. In most patients, a rapid decrease in PSA is seen within the first months of therapy, after which time PSA levels stabilize to a new baseline. The post treatment baseline approximates half of the pre-treatment value. Therefore, in typical patients treated with PROSCAR for six months or more, PSA values should be doubled for comparison to normal ranges in untreated men. For clinical interpretation, see PRECAUTIONS, EFFECTS ON PSA AND PROSTATE CANCER DETECTION.

 

PREGNANCY

PROSCAR is contraindicated for use in women when they are or may potentially be pregnant (see CONTRAINDICATIONS).

 

Because of the ability of Type II 5α-reductase inhibitors to inhibit conversion of testosterone to dihydrotestosterone, these drugs, including finasteride, may cause abnormalities of the external genitalia of a male fetus when administered to a pregnant woman.

 

EXPOSURE TO FINASTERIDE - RISK TO MALE FETUS

Women should not handle crushed or broken tablets of PROSCAR when they are or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus (see PREGNANCY). PROSCAR tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have riot been broken or crushed.

 

NURSING MOTHERS

PROSCAR is not indicated for use in women. It is not known whether finasteride is excreted in human milk.

 

PEDIATRIC USE

PROSCAR is not indicated for use in children. Safety and effectiveness in children have not been established.

 

SPECIAL PRECAUTION

Urethral stricture, infection, cancer, hypotonic bladder and other neurogenic disorders should be excluded before treatment with finasteride is started.

 

Caution is advised in treating patients with hepatic dysfunction since the drug is extensively metabolised in the liver.

 

1    2    3

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer